CORDIS · 115881 · H2020
RHAPSODY Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification - Sofia ref.: 115881
Coordinator: UNIVERSITE DE LAUSANNE (CH)
The stated goal of RHAPSODY is to define a molecular taxonomy of type 2 diabetes mellitus (T2D) that will support patient segmentation, inform clinical trial design, and the establishment of regulatory paths for the adoption of novel strategies for diabetes prevention and treatment. To address these goals, RHAPSODY will bring together prominent European experts, including the leaders of the diabetes-relevant IMI1 projects to identify, validate and characterize causal biomarkers for T2D subtypes and progression. Our plans are built upon: (a) access to large European cohorts with comprehensive …
About Horizon 2020 (2014–2020)
Horizon 2020 was the EU's flagship research and innovation programme for 2014–2020, with a budget of around €77 billion. It bundled FP7's strands with the EIT and the Competitiveness and Innovation Programme, introduced a stronger societal-challenge orientation, and pushed the funding logic toward closer-to-market innovation. New calls closed in 2020 but funded projects continued through 2024.
EU contribution: €8.1M awarded to the consortium. The project runs over approximately 5.5 years from 2016-04-01 to 2021-09-30.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from CH
see all →- HBP SGA1 — Human Brain Project Specific Grant Agreement 1720270 · H2020 · €89.0M
- HBP SGA2 — Human Brain Project Specific Grant Agreement 2785907 · H2020 · €88.0M
- ATTRACT2 — Breakthrough Innovation Programme for a Pan-European Detection and Imaging Eco-System – Phase-2101004462 · H2020 · €35.0M
- STEMBANCC — Stem cells for Biological Assays of Novel drugs and prediCtive toxiCology (StemBANCC)115439 · FP7 · €26.0M
- IABC PROGRAMME — iABC Programme115721 · FP7 · €24.3M
- ULTRA-DD — Unrestricted Leveraging of Targets for Research Advancement and Drug Discovery115766 · FP7 · €21.2M
Other H2020 projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon 2020 through a Joint programme of the members of the EUROfusion consortium633053 · DE · €678.8M
- H2020 — COST at a turning point: A unique framework for pan-European ST cooperation as clear demonstration of European values681463 · BE · €178.2M
- HBP SGA3 — Human Brain Project Specific Grant Agreement 3945539 · BE · €150.0M
- COVID-19 VACCINES — PROPOSAL FOR FUNDING RESEARCH DEVELOPMENT AND MANUFACTURING OF VACCINE AGAINST COVID-19101018100 · NO · €100.0M
- UNITE4TB — ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS101007873 · NL · €92.5M
- ERA4TB — EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS853989 · ES · €89.8M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon 2020 (2014–2020) programme, under the RIA funding scheme.
- What is the EU contribution?
- The European Commission contributes €8.1M.
- Which EU programme funds it?
- The project is funded under Horizon 2020 (2014–2020), call H2020-JTI-IMI2-2015-03-two-stage.
- Who coordinates the project?
- The project is coordinated by UNIVERSITE DE LAUSANNE (CH).
- What is the project timeline?
- The project runs from 2016-04-01 to 2021-09-30 — approximately 5.5 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 115881.